Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 282 participants.

Also called NCT05186818

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 282 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05186818
  • EudraCT 2021-003536-92
Other papers using this trial's data
  • Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial JAMA cardiology, 2024-11-01 DOI, PubMed 39230885, PMC11375526 In the PMC Open Access subset under CC BY-NC-ND.
  • Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy The New England journal of medicine, 2024-05-30 DOI, PubMed 38739079
  • Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial European heart journal, 2024-11-08 DOI, PubMed 39217447, PMC11544315 In the PMC Open Access subset under CC BY.
  • Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial Circulation, 2025-10-07 DOI, PubMed 40910168, PMC12493091 In the PMC Open Access subset under CC BY-NC-ND.
  • Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants Clinical and translational science, 2025-04 DOI, PubMed 40200648, PMC11979292 In the PMC Open Access subset under CC BY-NC-ND.
  • Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM Journal of the American Heart Association, 2024-08-06 DOI, PubMed 39056349, PMC11964075 In the PMC Open Access subset under CC BY.
  • Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy Journal of the American College of Cardiology, 2024-11-05 DOI, PubMed 39217563
  • Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM Journal of the American College of Cardiology, 2024-11-05 DOI, PubMed 39217569, PMC11975529 In the PMC Open Access subset under CC BY-NC-ND.
  • Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM Journal of the American College of Cardiology, 2024-11-05 DOI, PubMed 39352339
  • Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy Journal of the American College of Cardiology, 2024-11-05 DOI, PubMed 39217556

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05186818. Randomized; double masking; primary purpose treatment. Start 2022-02-01 (actual); primary completion 2023-11-10 (actual). Results posted on 2026-03-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Acronym
SEQUOIA-HCM
Condition
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Intervention (Drug)
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
Intervention (Drug)
Placebo to match aficamten
Lead sponsor
Cytokinetics (class: industry)
Collaborator
Corxel Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05186818
Content hash
45d8de95816943d08ade1e7b63bf087ba46e4bc3c1405b7967ef7562ca0c6456